In addition to a lack of representation in life-saving clinical trials, Black patients also face obstacles to accessing GLP-1 medications, including cost, insurance restrictions, provider bias, and medication shortages
In one such trial the 68-week STEP 1 study adults receiving once-weekly subcutaneous semaglutide 2.4 mg demonstrated a mean body weight reduction of 14.9%, compared with 2.4% in the placebo group [1]
Managing injection site reactions Redness, swelling, or itching at the injection site affects a subset of patients
7 Furthermore, FFA2-deficient mice have been reported to demonstrate impaired glucose tolerance on a normal chow diet
Il peut aussi se prsenter sous forme de complment alimentaire avec le glutathion rduit (GSH) ou en prenant des prcurseurs comme la glutamine